Institution
University of Melbourne
Education•Melbourne, Victoria, Australia•
About: University of Melbourne is a education organization based out in Melbourne, Victoria, Australia. It is known for research contribution in the topics: Population & Mental health. The organization has 57194 authors who have published 174878 publications receiving 6338400 citations. The organization is also known as: Melbourne University & The University of Melbourne.
Papers published on a yearly basis
Papers
More filters
TL;DR: The GCTA software is a versatile tool to estimate and partition complex trait variation with large GWAS data sets and focuses on the function of estimating the variance explained by all the SNPs on the X chromosome and testing the hypotheses of dosage compensation.
Abstract: For most human complex diseases and traits, SNPs identified by genome-wide association studies (GWAS) explain only a small fraction of the heritability. Here we report a user-friendly software tool called genome-wide complex trait analysis (GCTA), which was developed based on a method we recently developed to address the “missing heritability” problem. GCTA estimates the variance explained by all the SNPs on a chromosome or on the whole genome for a complex trait rather than testing the association of any particular SNP to the trait. We introduce GCTA's five main functions: data management, estimation of the genetic relationships from SNPs, mixed linear model analysis of variance explained by the SNPs, estimation of the linkage disequilibrium structure, and GWAS simulation. We focus on the function of estimating the variance explained by all the SNPs on the X chromosome and testing the hypotheses of dosage compensation. The GCTA software is a versatile tool to estimate and partition complex trait variation with large GWAS data sets.
5,867 citations
TL;DR: This paper defines Cloud computing and provides the architecture for creating Clouds with market-oriented resource allocation by leveraging technologies such as Virtual Machines (VMs), and provides insights on market-based resource management strategies that encompass both customer-driven service management and computational risk management to sustain Service Level Agreement (SLA) oriented resource allocation.
5,850 citations
TL;DR: Global health has steadily improved over the past 30 years as measured by age-standardised DALY rates, and there has been a marked shift towards a greater proportion of burden due to YLDs from non-communicable diseases and injuries.
5,802 citations
TL;DR: In the Global Burden of Disease Study 2013 (GBD 2013) as discussed by the authors, the authors used the GBD 2010 methods with some refinements to improve accuracy applied to an updated database of vital registration, survey, and census data.
5,792 citations
Brigham and Women's Hospital1, University of California, San Diego2, University of California, Davis3, Rush University Medical Center4, University of Washington5, Washington University in St. Louis6, University of Tokyo7, Mayo Clinic8, Oregon Health & Science University9, University of Texas at Dallas10, University of Melbourne11, Eli Lilly and Company12, Columbia University13, University of California, San Francisco14, Alzheimer's Association15, National Institutes of Health16
TL;DR: A conceptual framework and operational research criteria are proposed, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies and it is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD.
Abstract: The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long "preclinical" phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from "normal" cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease-modifying therapies may be most efficacious.
5,671 citations
Authors
Showing all 57958 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| David J. Hunter | 213 | 1836 | 207050 |
| Christopher J L Murray | 209 | 754 | 310329 |
| Tamara B. Harris | 201 | 1143 | 163979 |
| Martin White | 196 | 2038 | 232387 |
| Patrick W. Serruys | 186 | 2427 | 173210 |
| Alan D. Lopez | 172 | 863 | 259291 |
| Mika Kivimäki | 166 | 1515 | 141468 |
| Andrew P. McMahon | 162 | 415 | 90650 |
| David W. Johnson | 160 | 2714 | 140778 |
| Tien Yin Wong | 160 | 1880 | 131830 |
| Arthur W. Toga | 159 | 1184 | 109343 |
| Robert G. Webster | 158 | 843 | 90776 |
| Mark E. Cooper | 158 | 1463 | 124887 |
| Christian Gieger | 157 | 617 | 113657 |
| Philip Cohen | 154 | 555 | 110856 |